Agomab Therapeutics NV
agomab.comWhat Do They Do?
Develops small-molecule and antibody drug candidates for fibro-inflammatory diseases, including intestinal, lung and liver conditions.
20-F for FY2025, filed Apr 23, 2026Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory…View ↗
We are advancing a pipeline of novel product candidates for chronic fibro-inflammatory disorders with well-validated targets, significant…View ↗
Discovery and preclinical portfolio: We have a robust discovery pipeline including several programs in the early stages of development.…View ↗
Who Do They Compete With?
Competes with Merck &, Sanofi, Roche Holding, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Amgen, RedX Pharma, Palisade Bio, Enveda, Teva Pharma, Pfizer, Spyre Therapeutics, Xencor, Caldera Therapeutics, Earendil Labs, Abivax SA, Eli Lilly, AstraZeneca, United Therapeutics, and Avalyn Pharma
20-F for FY2025, filed Apr 23, 2026There are a number of large biopharmaceutical companies that are currently pursuing the development of products for the treatment of…View ↗
Loading...
